4//SEC Filing
Mainolfi Nello 4
Accession 0000950170-25-081199
CIK 0001815442other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 6:30 PM ET
Size
8.5 KB
Accession
0000950170-25-081199
Insider Transaction Report
Form 4
Mainolfi Nello
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2025-06-03$2.08/sh+30,000$62,400→ 690,482 total - Sale
Common Stock
2025-06-03$49.00/sh−30,000$1,470,000→ 660,482 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-03−30,000→ 465,559 totalExercise: $2.08Exp: 2029-11-13→ Common Stock (30,000 underlying)
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
- [F2]This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025.
- [F3]The shares underlying this stock option are fully vested and exercisable.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001821189
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 6:30 PM ET
- Size
- 8.5 KB